SystImmune -Model BL-M02D1-ADC -Antibody Drug Conjugates (ADC) Molecules
FromSystImmune Inc.
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells.
Most popular related searches
drug conjugate
cancer cell
solid tumor
immune effector
innate immunity
clinical trial
drug molecule
immune functional
patient enrollment
cancerous target
The ADC BL-M02D1 is a TROP2 specific antibody drug conjugate. Due to its TROP2 binding, BL-M02D1 has rapid internalization and specificity for a variety of TROP2 expressing solid tumors and secondarily, through a wt FC receptor mediating innate immune effector functions toward the cancer cells. Upon antibody mediated internalization, BL-M02D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death.
BL-M02D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of TROP2+ solid tumor indications.
